Copyright
©The Author(s) 2021.
World J Diabetes. Jul 15, 2021; 12(7): 932-938
Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.932
Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.932
Figure 1 Potential benefits of sodium-glucose co-transporter-2 inhibitors in treatment of different metabolic and cardiovascular features of polycystic ovary syndrome.
NAFLD: Non-alcoholic fatty liver disease; PCOS: Polycystic ovary syndrome; SGLT-2i: Sodium-glucose co-transporter-2 inhibitors; T2DM: Type 2 diabetes.
- Citation: Marinkovic-Radosevic J, Cigrovski Berkovic M, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World J Diabetes 2021; 12(7): 932-938
- URL: https://www.wjgnet.com/1948-9358/full/v12/i7/932.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i7.932